Ranbaxy's Abacavir in WHO pre-qualification list of ARVs

New Delhi, Aug 1 (UNI) Pharmaceutical major Ranbaxy Laboratories Ltd today said the World Health Organisation has approved and included its Abacavir, an anti-retroviral in its pre-qualification list.

The product will be manufactured at its WHO pre-qualified site at Paonta Sahib, a company statement said.

With the inclusion of Abacavir 300 tablets, Ranbaxy now has 18 ARVs on the WHO pre-qualification list, including three USFDA approvals.

UNI SR AK RAI1342